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ABSTRACT
Patient reported outcomes (PROs) are
commonly integrated into clinical trials for
new cancer therapies or treatment modalities;
however, beyond a cursory review during the
registration process for a new drug, these
important measures of patient satisfaction and
cost-effectiveness are often under-used in daily
practice. We cite literature under-scoring the
value of PROs not only in clinical trials, but in
practical decision making and how such metrics
can help guide the oncologist and the patient in
choosing the best and most cost-effective
therapy for their cancer. This is especially
critical with the advent of new
immunotherapies that are proving to be
therapeutically beneficial for many patients,
but not all, and at substantial cost in terms of
toxicities and financial impact.
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The past decade has seen remarkable progress in
cancer treatment. Much of this has been due to
the improvements in the ability to identify
potentially targetable biomarkers. The
identification of genetic aberrations has led to
new therapies for lung cancer that are now
achieving response rates approaching 90% in
select patient subsets with tumors that are
enriched for the specific target [1]. Better
understanding of the pathways involved in
immune tolerance and rejection have led to
development of therapies to modulate those
pathways and have turned previously
untreatable cancers into chronic diseases.
After a slow start, we are now seeing an
explosive growth in development of new drugs
in these areas. In 2015 alone, there were no less
than 32 approvals by the Food and Drug
Administration (FDA) for new agents or new
indications for existing agents in the treatment
of various cancers [2]. The FDA has already
granted 12 approvals for the first half of 2016.
While this rapid expansion offers new
therapeutic options for patients where they
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did not exist before, it does not come without a
cost.
Several of the recent FDA approvals have
been for ‘‘me-too’’ drugs, agents that use a
similar mechanism of action and with similar
toxicity profiles as agents already on the market.
For example, nivolumab, an antibody that
targets the Programmed Death (PD-1) receptor,
which had already demonstrated activity in
metastatic melanoma, was first approved in
March 2015 for second-line therapy of
advanced squamous non-small cell lung cancer
(NSCLC) in patients progressing on or after
prior platinum-based chemotherapy [3, 4]. In
October, 2015, the FDA expanded nivolumab’s
indication to include NSCLCs of the
adenocarcinoma variety as well [5, 6]. That
same month, the FDA granted approval for
pembrolizumab as second-line therapy in
platinum-treated NSCLC patients, but with the
requirement that they demonstrated positive
Program Death Ligand 1 (PD-L1) expression
[7, 8]. Currently there are a number of
additional PD-1/PD-L1 inhibitors going
through clinical trials for NSCLC and other
solid tumors.
These agents also have shown activity in
other cancers, leading to expanded FDA
approvals for melanoma, renal cell carcinoma,
and bladder urothelial cancers among others.
Other targeted agents are now available or being
studied for hematologic malignancies, breast
cancers, head and neck cancers, brain
metastases, and others. While some of this
rapid therapeutic expansion is driven by a
need to improve existing treatment options,
marketing and pharmaceutical patents also play
a role as companies jockey to be the first to gain
FDA-approval for their particular drug.
The cost of these new therapies can be
staggering. A Wall Street Journal report in
2015 estimated the cost of nivolumab and
ipilimumab for metastatic melanoma at
$141,000 for the first 12 weeks and $256,000
for the first year of therapy [9]. Nivolumab
monotherapy is approved for both squamous
and non-squamous NSCLC as second-line
therapy after prior platinum-based therapy, as
noted earlier. This is based on the CheckMate
trials comparing nivolumab versus docetaxel
[4, 6]. Several countries have tried to analyze the
cost-effectiveness of nivolumab in this setting.
A United Kingdom study in 2015 reported that
nivolumab in squamous NSCLC was not
cost-effective per quality-adjusted life years
(QALY) gained, and a similar Canadian study
this year comparing nivolumab with docetaxel
and erlotinib in NSCLC showed nivolumab with
the highest per-patient cost [10, 11]. A more
recent Swiss study looking at nivolumab versus
docetaxel in non-squamous NSCLC using
clinical data from the CheckMate-057 trial
measured incremental cost effectiveness ratios
(ICER) per QALY-gained [12]. The study showed
that for all patients treated, nivolumab had
much higher ICERs (in Swiss francs) than
docetaxel; however, for patients with positive
PD-L1 expression [ 1% or [10% by
immunohistochemical (IHC) staining], the
nivolumab ICERs were lower and felt to be
cost-effective based on a willingness-to-pay
(WTP) threshold specific for the Swiss
health-care system. Thus, the authors felt that
for nivolumab to be cost-effective either the
drug price and/or dose needed to be reduced or
treatment based on PD-L1 testing should be
considered.
Even for patients with good insurance
coverage, this can be a daunting price tag. The
economics of health care is complex and
beyond the scope of this editorial. Health care
policy is a moving target, but one that occupies
a major component of our federal budget.
Reimbursement for medical care is moving
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towards value-based outcomes, rather than
procedural or volume-based plans [13].
Providers will not be paid for simply seeing
more patients, ordering more tests, and
delivering more treatments. The quality of
those interactions, including patient
outcomes, will be important in determining
value-based reimbursement levels.
With the plethora of agents emerging,
clinicians are confronted with challenging
choices in determining the best treatment
option for specific patients. Patients are also
confronted with decisions related to the
procedures involved in diagnosis to the
potential side effects and costs of new
therapies. Insurance coverage and access to
centers familiar with these procedures and
treatments present potential barriers for many
patients. It is in this climate that patient
reported outcomes (PROs) are increasingly
important as we try to determine the best
value of care and use of these new
technologies and treatment options [14, 15].
In 2013, the National Quality Forum (NQF),
an organization that reviews and endorses
quality metrics published the conclusions of
an expert panel charged with developing
standards for metrics in PRO development
[16]. Their work was endorsed by the
International Society for Quality of Life
Research [17]. Their six-step pathway consisted
of the following: identify performance concerns
for the population of interest; determine
meaningful outcomes; develop PROs to
measure those outcomes; determine
PRO-performance measures (PRO-PMs);
conduct pilot testing; standardize guidelines.
PROs have already demonstrated impact on
value care decision making. The American
Society of Clinical Oncology (ASCO) used the
NQF model to pilot specific oncology programs
for pain assessment in patients with bone
metastases and post-chemotherapy nausea
control [14]. For patients with cancer-related
pain, the work group established that the Brief
Pain Inventory (BPI) was the most appropriate
tool for PRO measurement of pain [18]. Their
consensus was that a PRO Performance Measure
should assess the proportion of patients with
metastatic disease with a worst pain score of C4
as a group that would likely benefit from
modification of their analgesic regimens.
Similarly, for nausea due to moderately or
highly emetogenic chemotherapy, their
consensus developed a PRO-PM for patients
who develop nausea within the first week after
receiving such chemotherapy and to rate their
worst nausea and frequency of nausea with
potential interventions to modify the
anti-emetic regimens for such patients.
These are two examples where PRO-PMs are
helpful in modifying treatment algorithms to
achieve value based and patient preferred
therapy. There are many areas in cancer
treatment that could benefit from PRO-PMs
incorporated into the treatment strategy or as
part of an ongoing clinical trial. As an example,
identifying targetable mutations or gene
re-arrangements currently requires adequate
tissue samples, often necessitating invasive and
painful biopsy procedures, sometimesmore than
once. The risk and cost of these procedures is not
insignificant and patient compliance can be
negatively impacted. Research is ongoing to
develop liquid biopsies, circulating free tumor
DNA, which may obviate the need for invasive
surgical biopsies in many cases [19, 20]. Patients
uniformly say they would prefer and be more
compliant with liquid biopsies as an alternative
to tissue sampling if the accuracy of such testing
was as good [21].
Similarly, PRO assessment of quality of life
metrics and toxicities can help define a
value-based choice of treatment for a particular
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cancer. Coming to clinic for treatment once
every 3 weeks versus every 2 weeks may be an
important variable for patients still trying to
balance a family or work life with their
treatment. Co-pays and provider costs for the
patient, not covered by their insurance, may be
better absorbed with less frequent treatment
visits. If toxicities on the two treatments are
otherwise identical and the efficacy comparable,
then patients may be better served with a 3-week
frequency. This is an example of PRO influencing
value based care decisions.
These factors create an imperative that we
look at our new therapeutic and diagnostic
advances not simply as clinical breakthroughs,
but also in the context of their impact on health
care economics and patient outcomes, including
quality and quantity of life and at what cost,
both physically and financially. While response
rates, progression free and overall survival, and
toxicity grades are important, including PRO
surveys and other mechanisms as part of the
clinical trial could provide valuable insight into
the patient’s perspective and the treatments’
impact on their life. These added metrics,
combined with clinical outcomes, could help
determine the best value approach for a
particular diagnosis and a patient centered care
that would be cost effective as well.
The previously described ASCO workgroup’s
concluding statements that ‘‘patient
self-reporting affords the opportunity to
understand better the impact of care processes
on how patients feel (and can optimize) good
clinical practice’’ is indicative of how important
this is to patients. As such, it is important to
incorporate such metrics into the evaluation of
new therapies in order to provide quality
effective care along with quality of life and
control of cost. ASCO has lobbied for
incorporating PROs into clinical practice. As
such, it may be time to standardize PRO surveys.
The six-step approach outlined by the NQF may
be one example. Validation of surveys is
important. At MD Anderson Cancer Center,
we have begun incorporating the MD Anderson
Symptom Inventory (MDASI), a brief
multi-symptom questionnaire, as a scale for
outcomes evaluation of patients on various
immunotherapy trials [22]. With the
consensus recommendations of organizations
such as ASCO, the NQF, and the International
Society for Quality of Life Research, amongst
others, might it be timely to incorporate
routinely PRO-PMs and PRO surveys in clinical
trials and registration studies as part of the
approval process for new treatment paradigms
and/or individual drugs? The future economic
health of cancer care may depend on it.
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